April 16, 2014 5:20 AM ET


Company Overview of Biolex Therapeutics, Inc.

Company Overview

Biolex Therapeutics, Inc. operates as a biopharmaceutical company. It offers Locteron, a controlled-release interferon alfa for the treatment of hepatitis C; BLX-155, a thrombolytic or clot buster to dissolve blood clots; and BLX-301, an antibody for the treatment of B-cell lymphoma. Biolex Therapeutics, Inc. has a research and development collaboration with Merial Limited to produce veterinary vaccines. Biolex Therapeutics, Inc. was founded in 1997 under the name Biolex, Inc. and changed its name in 2007. The company is based in Pittsboro, North Carolina. On July 3, 2012, Biolex Therapeutics, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the ...

158 Credle Street

Pittsboro, NC 27312

United States

Founded in 1997

106 Employees





Key Executives for Biolex Therapeutics, Inc.

Chief Executive Officer
Age: 59
Executive Chairman
Age: 45
Chief Financial Officer and Senior Vice President of Finance
Age: 53
Chief Operating Officer and Senior Vice President of Research & Development
Age: 60
Chief Business Officer and Senior Vice President
Compensation as of Fiscal Year 2013.

Similar Private Companies By Industry

Company Name Region
Alopexx Pharmaceuticals, LLC United States
Proliant Inc. United States
Vitaphore Corporation United States
Maxygen, Inc. United States
Biothera, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Biolex Therapeutics, Inc., please visit www.biolex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.